Figure 5
XL-DNA enhances anti-cancer efficacy of doxorubicin in the AOM/DSS-induced colonic cancer model. A. Two cycles of dextran sodium sulfate (DSS) treatment in combination with azoxymethane (AOM) resulted in more than 83% incidence of colonic neoplasms that were most frequently observed in the middle and distal colon. Eight weeks after AOM injection, doxorubicin (Dox, 1 or 2 mg/kg) and/or XL-DNA (2.5 or 5 mg/kg) were i.v injected. Each group had twelve mice except for the normal control group, which had ten mice. B. Changes in mouse body weight were monitored. C-E. Colons were obtained 15 weeks after AOM injection. C. Macroscopic features of colon. D. H&E staining of colon sections. Arrow indicates tumor. Magnification: 40x. E. The number of colonic polyps ≥3 mm or <3 mm in size (n = 8). The incidence of colonic polyp formation was zero in the normal control group (not shown in figure). Values are mean ± SEM (n = 8). *, Significantly different from AOM/DSS alone group (p < 0.05). N.S., not significant from AOM/DSS alone group. Veh, vehicle.